Instanyl

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Fentanil citrat

Available from:

Takeda Pharma A/S

ATC code:

N02AB03

INN (International Name):

fentanyl

Therapeutic group:

analgetici

Therapeutic area:

Pain; Cancer

Therapeutic indications:

Instanyl je indiciran za upravljanje probavnom boli kod odraslih koji već primaju opioidnu terapiju za kroničnu bol u raku. Probijanje boli je prolazno pogoršanje boli koja se javlja na pozadini drugačije kontrolirane upornosti boli.  Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Product summary:

Revision: 36

Authorization status:

odobren

Authorization date:

2009-07-20

Patient Information leaflet

                                90
B. UPUTA O LIJEKU
91
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
_ _
INSTANYL 50 MIKROGRAMA/DOZA SPREJ ZA NOS, OTOPINA
INSTANYL 100 MIKROGRAMA/DOZA SPREJ ZA NOS, OTOPINA
INSTANYL 200 MIKROGRAMA/DOZA SPREJ ZA NOS, OTOPINA
fentanil
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Instanyl i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati Instanyl
3.
Kako primjenjivati Instanyl
4.
Moguće nuspojave
5.
Kako čuvati Instanyl
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE INSTANYL I ZA ŠTO SE KORISTI
Instanyl sadrži djelatnu tvar fentanil i pripada skupini jakih
analgetika (lijekova za ublažavanje boli)
koje zovemo opioidima. Opioidi djeluju blokirajući bolne signale
prema mozgu.
Instanyl djeluje brzo i koristi se za ublažavanje probojne boli kod
odraslih bolesnika s rakom koji već
uzimaju opioidnu terapiju za trajnu bol. Probojna bol je dodatna
iznenadna bol koja se pojavljuje
usprkos redovitoj terapiji opioidima za ublažavanje boli.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE PRIMJENJIVATI INSTANYL
NEMOJTE PRIMJENJIVATI INSTANYL
-
ako ste alergični na fentanil ili bilo koji drugi sastojak ovog
lijeka (naveden u dijelu 6);
-
ako za kontrolu stalne boli ne koristite propisani opioidni lijek
(npr. kodein, fentanil,
hidromorfon, morfin, oksikodon, petidin) redovito, svaki dan prema
rasporedu, najmanje tjedan
dana. Ako niste uzimali ove lijekove ne smijete uzeti Instanyl jer
može povećati rizik od
opasnog usporavanja disanja i/ili p
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Instanyl 50 mikrograma/doza sprej za nos, otopina
Instanyl 100 mikrograma/doza sprej za nos, otopina
Instanyl 200 mikrograma/doza sprej za nos, otopina
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Instanyl 50 mikrograma/doza sprej za nos, otopina
Jedan ml otopine sadrži fentanilcitrat što odgovara 500 mikrograma
fentanila.
1 doza (100 mikrolitara) sadrži 50 mikrograma fentanila.
Instanyl 100 mikrograma/doza sprej za nos, otopina
Jedan ml otopine sadrži fentanilcitrat što odgovara 1000 mikrograma
fentanila.
1 doza (100 mikrolitara) sadrži 100 mikrograma fentanila.
Instanyl 200 mikrograma/doza sprej za nos, otopina
Jedan ml otopine sadrži fentanilcitrat što odgovara 2000 mikrograma
fentanila.
1 doza (100 mikrolitara) sadrži 200 mikrograma fentanila.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Sprej za nos, otopina (sprej za nos)
Bistra, bezbojna otopina.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Instanyl je indiciran za zbrinjavanje probojne boli u odraslih koji
već uzimaju opioidnu terapiju
održavanja zbog kronične karcinomske boli. Probojna bol je prolazna
egzacerbacija boli koja se javlja
povrh inače kontrolirane trajne boli.
Bolesnicima koji uzimaju opioidnu terapiju održavanja smatraju se oni
koji uzimaju barem 60 mg
oralnog morfina dnevno, barem 25 mikrograma transdermalnog fentanila
na sat, barem 30 mg
oksikodona dnevno, barem 8 mg oralnog hidromorfona dnevno ili
ekvivalentnu analgetsku dozu
drugog opioida tijekom jednog tjedna ili dulje.
4.2
DOZIRANJE I NAČIN PRIMJENE
Liječenje treba započeti i nadzirati liječnik s iskustvom u
primjeni opioidne terapije u bolesnika s
karcinomom. Liječnici trebaju imati na umu mogućnost zlouporabe,
pogrešne primjene, ovisnosti i
predoziranja fentanilom (vidjeti dio 4.4).
Doziranje
Dozu treba individualno titrirati do one koja pruža adekvatnu
analgeziju uz prihvatljive nuspojave.
Tijekom titracije doze bolesnike se mora pozorno pratiti.
Titracija do veće doze zahti
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-10-2023
Public Assessment Report Public Assessment Report Bulgarian 23-07-2019
Patient Information leaflet Patient Information leaflet Spanish 19-10-2023
Public Assessment Report Public Assessment Report Spanish 23-07-2019
Patient Information leaflet Patient Information leaflet Czech 19-10-2023
Public Assessment Report Public Assessment Report Czech 23-07-2019
Patient Information leaflet Patient Information leaflet Danish 19-10-2023
Public Assessment Report Public Assessment Report Danish 23-07-2019
Patient Information leaflet Patient Information leaflet German 19-10-2023
Public Assessment Report Public Assessment Report German 23-07-2019
Patient Information leaflet Patient Information leaflet Estonian 19-10-2023
Public Assessment Report Public Assessment Report Estonian 23-07-2019
Patient Information leaflet Patient Information leaflet Greek 19-10-2023
Public Assessment Report Public Assessment Report Greek 23-07-2019
Patient Information leaflet Patient Information leaflet English 19-10-2023
Public Assessment Report Public Assessment Report English 23-07-2019
Patient Information leaflet Patient Information leaflet French 19-10-2023
Public Assessment Report Public Assessment Report French 23-07-2019
Patient Information leaflet Patient Information leaflet Italian 19-10-2023
Public Assessment Report Public Assessment Report Italian 23-07-2019
Patient Information leaflet Patient Information leaflet Latvian 19-10-2023
Public Assessment Report Public Assessment Report Latvian 23-07-2019
Patient Information leaflet Patient Information leaflet Lithuanian 19-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-10-2023
Public Assessment Report Public Assessment Report Lithuanian 23-07-2019
Patient Information leaflet Patient Information leaflet Hungarian 19-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 19-10-2023
Public Assessment Report Public Assessment Report Hungarian 23-07-2019
Patient Information leaflet Patient Information leaflet Maltese 19-10-2023
Public Assessment Report Public Assessment Report Maltese 23-07-2019
Patient Information leaflet Patient Information leaflet Dutch 19-10-2023
Public Assessment Report Public Assessment Report Dutch 23-07-2019
Patient Information leaflet Patient Information leaflet Polish 19-10-2023
Public Assessment Report Public Assessment Report Polish 23-07-2019
Patient Information leaflet Patient Information leaflet Portuguese 19-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 19-10-2023
Public Assessment Report Public Assessment Report Portuguese 23-07-2019
Patient Information leaflet Patient Information leaflet Romanian 19-10-2023
Public Assessment Report Public Assessment Report Romanian 23-07-2019
Patient Information leaflet Patient Information leaflet Slovak 19-10-2023
Public Assessment Report Public Assessment Report Slovak 23-07-2019
Patient Information leaflet Patient Information leaflet Slovenian 19-10-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 19-10-2023
Public Assessment Report Public Assessment Report Slovenian 23-07-2019
Patient Information leaflet Patient Information leaflet Finnish 19-10-2023
Public Assessment Report Public Assessment Report Finnish 23-07-2019
Patient Information leaflet Patient Information leaflet Swedish 19-10-2023
Public Assessment Report Public Assessment Report Swedish 23-07-2019
Patient Information leaflet Patient Information leaflet Norwegian 19-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 19-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 19-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 19-10-2023

Search alerts related to this product

View documents history